Observational study of achieving LDL targets with Rovazet tablets in dyslipidemia
Official title: A Multi-center, Prospective, Observational Study to Evaluate Achieving LDL-cholesterol Target Level to Treat With Rovazet Tab. With Dyslipidemia Patients
Run by HK inno.N Corporation · NCT07924345 · Data updated 2026-11-12
This study follows patients with dyslipidemia who are prescribed Rovazet to see how well reaching LDL targets works in routine care over 48 weeks.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 6713 (estimated) |
| Sponsor | HK inno.N Corporation Industry-sponsored |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | May 22, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07924345 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 19 years or older with dyslipidemia for whom Rovazet treatment is clinically indicated and prescribed.
✕Probably not a fit
Patients for whom Rovazet is not effective or not tolerated may not see LDL improvements.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, prospective observational study tracks adults with dyslipidemia who have already been prescribed Rovazet as part of standard clinical practice. Data are collected at baseline, Week 24, and Week 48 to observe effectiveness and safety in real-world use. Investigators determine eligibility and treatment decisions in routine visits, with no intervening study-imposed changes. The study aims to describe patterns of LDL response and safety events in a real-world setting across participating sites led by HK inno.N Corporation.
Why it matters
Potential benefit: If Rovazet achieves LDL targets in real-world use, patients may experience improved cholesterol control with standard care.
How similar studies have gone: Other observational programs have explored real-world effectiveness of lipid-lowering therapies, with variable results depending on population and adherence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 19 years or older who have been diagnosed with dyslipidemia. * Patients for whom treatment with Rovazet tablets has been determined based on the investigator's medical judgment. * Patients with LDL-C and HDL-C test results obtained within 3 months before the date of enrollment. * Individuals who have voluntarily provided written informed consent to participate in this study. Exclusion Criteria: * Patients for whom Rovazet tablets are contraindicated according to the contraindications listed in the approved product labeling. * Patients whom the investigator considers unsuitable for participation in this study for any other reason.
Where it's running
-
HK inno.N Corporation
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Yongan Jeong
- Email: yongan.jeong@inno-n.com
- Phone: +82-31-5176-4673
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Early Triple Lipid-Lowering Therapy After ACS
This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.
-
Kodo Millet Porridge and Gut Health in Overweight and Obese Adults
This study tests whether daily intake of Kodo millet porridge for 12 weeks can improve gut bacteria and metabolic health in adults who are overweight or obese.
-
Taiwan green propolis for MASLD and lipid/metabolic issues
This study tests whether Taiwan green propolis capsules can improve blood lipids and body fat in adults with MASLD compared to a placebo over 12 weeks.
-
EHR-guided LDL cholesterol optimization after a heart event
A pharmacist-guided program using electronic health records to help adults in Alberta reach LDL goals after a heart event by adjusting medications and ordering tests.
-
Two-drug interaction study of UIC202601 and UIC202602 in healthy adults
This study tests whether combining two investigational drugs changes how they behave in the body and whether the combination is safe in healthy volunteers.
-
Polypill Approach for Multiple Cardiovascular Risk Factors
Researchers are testing a fixed-dose pill strategy to help people aged 50–75 with high blood pressure, high cholesterol, and diabetes see if it lowers their heart-disease risk and reduces future events.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.